Varian and GenesisCare have today (Wednesday, October 24, 2018) announced the signing of a memorandum of understanding for the formation of a strategic partnership for cancer care research and to increase access to advanced cancer care across Australia.
The partnership between Varian, a global leader in developing and delivering cancer care solutions, and GenesisCare, Australia’s largest private provider of cancer care, will involve the roll-out of a range of world-leading hardware and software over the ensuing five years.
An estimated 138,000 new cancer cases will be diagnosed in Australia this year, with that number set to rise to 150,000 by 2020.1 Radiation therapy contributes to 40 per cent of all cancer cures world-wide as well as relieving symptoms, such as pain, and improving the quality of life for many others.2
According to radiation oncologist Associate Professor Peter O’Brien, GenesisCare’s Australian Chief Medical Officer, radiation therapy is a highly effective cancer treatment, although it is under-utilised in Australia despite only costing less than nine cents in every dollar spent on cancer diagnosis and treatment.2
“The advances in radiation therapy technology in recent years have been quite phenomenal and we’re now able to use platforms that give us pinpoint accuracy and streamlined access to patient data. This helps us deliver better outcomes for our patients, which is ultimately what matters most,” he said.
The relationship is intended to cover up to a total of 70 Varian linear accelerators and Varian Eclipse™ treatment planning software as the preferred GenesisCare solution provider globally, the partnership will also include support of skin cancer clinical trials utilising Varian RapidArc® technology.
“Improving the quality of life for skin cancer patients is a major research focus for GenesisCare, so we’re thrilled that Varian will be investing in new skin cancer trials as part of this partnership. Radiation therapy can be transformative for people with chronic skin cancer, and we aim to be at the forefront of research that can advance treatment for patients, both in Australia and internationally,” A/Prof O’Brien added.
Skin cancer is among the nation’s most prevalent cancers.3 It accounts for around 80 per cent of new cancer diagnoses, with two-in-three Australians diagnosed with a skin cancer by 70 years of age.4
GenesisCare Chief Executive Officer, Dan Collins, says the partnership with Varian will support advances in radiation therapy and the evolution of Varian’s products and services to get proven new technology to patients as quickly as possible.
“GenesisCare is excited to be partnering with Varian to accelerate the roll-out of ground-breaking radiation therapy technology that’s set to improve clinician efficiency and accuracy. We’re committed to increasing access to world class patient care, and will be installing up to 70 new linear accelerators internationally, as part of this agreement. This will mean a big boost in high quality cancer treatment in areas of need,” said Mr Collins.
Varian Australasia Managing Director Chris Cowley says the partnership with GenesisCare represents another significant step towards Varian’s aim of achieving a world free from fear of cancer.
“Varian is delighted to be partnering with GenesisCare to increase Australian patient access to our radiation technology, and ultimately improve the cancer treatment experience, and hopefully outcomes, for those in need.
“We are dedicated to combining the ingenuity of people with the power of data and technology to achieve new victories against cancer, and are therefore thrilled that GenesisCare has put their faith in our products with this volume commitment to both our hardware and software platforms,” Mr Cowley said.
The partnership will also focus on the emerging field of theranostics, also known as molecular targeted radiation. Theranostics uses nanoscience to unite diagnostic and therapeutic applications to form a single cancer fighting agent. Utilising Varian’s expertise in image-guided technology and GenesisCare’s experience in clinical and research domains, Varian and GenesisCare will partner to develop image-guided treatment monitoring solutions in this evolving area.
About Varian’s hardware & software
Halycon™ is a cutting-edge, image-guided, volumetric intensity modulated radiotherapy system designed to accelerate and simplify the imaging, therapy, and even installation of the machine and the training required to use it.
Truebeam® radiotherapy system is an advanced medical linear accelerator fully-integrated for image-guided radiotherapy and radiosurgery, designed to treat targets with enhanced speed and accuracy.
Eclipse™ treatment planning system is an integrated, comprehensive system supporting radiation treatment such as photon, FFF beams, protons, electrons, external beams, low-dose-rate brachytherapy and cobalt therapy.
HyperArc™ high-definition radiotherapy is an end-to-end information software solution for the treatment of multiple, well-defined brain tumours with high-doses of radiation therapy that pinpoint the tumours via a fully automated system.
Gated RapidArc® radiotherapy makes it possible to monitor patient breathing and compensate for tumour motion while quickly delivering dose during a continuous rotation around the patient.
Varian is a leader in developing and delivering cancer care solutions and is focused on creating a world without fear of cancer. Globally headquartered in Palo Alto, California, Varian has operated in Australasia since 1999, and now employs over 70 people. To learn more about Varian, head to their website or follow Varian Australasia on Twitter @variananz and connect via LinkedIn.
GenesisCare delivers treatment to people with cancer and heart disease, the two largest disease burdens globally. Its purpose is to design care experiences that get the best possible life outcomes. The organisation employs more than 2,500 highly trained healthcare professionals and support staff across Australia, Europe and now China, and sees more than 160,000 people each year at more than 130 locations. For cancer treatment, that includes 12 centres in the UK, 21 in Spain and 30 in Australia. GenesisCare also offers cardiology and sleep services at more than 80 locations across Australia. It is committed to leading the change in how care is designed and given, and is currently leading or participating in more than 100 clinical trials. For more information visit our website.
1. Cancer Council Australia. Skin Cancer. https://www.cancer.org.au/about-cancer/types-of-cancer/skin-cancer.html [Last accessed October 2018].
2. The Royal Australian and New Zealand College of Radiologists. About Radiation Oncology. Benefits and Effectiveness. https://www.targetingcancer.com.au/about-radiation-oncology/benefits-and-effectiveness/ [Last accessed October 2018].
3. The Royal Australian and New Zealand College of Radiologists. Concern at Underuse of Radiation Therapy in Cancer Treatment. www.ranzcr.com/whats-on/news-media/192-concern-at-underuse-of-radiation-therapy-in-cancer-treatment [Last accessed October 2018].
4. Cancer Council of Australia. Cancer in Australia. Available at: https://www.cancer.org.au/about-cancer/what-is-cancer/facts-and-figures.html [Last accessed October 2018].